
    
      This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in
      combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab
      (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.
    
  